NasdaqCM - Nasdaq Real Time Price • USD
Galectin Therapeutics Inc. (GALT)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
Low Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
High Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
Year Ago EPS | -0.19 | -0.15 | -0.74 | -0.66 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | -- | -- | -- | 36.32M |
Low Estimate | -- | -- | -- | 36.32M |
High Estimate | -- | -- | -- | 36.32M |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.21 | -0.21 | -0.16 | -0.16 |
EPS Actual | -0.19 | -0.15 | -0.24 | -0.16 |
Difference | 0.02 | 0.06 | -0.08 | 0 |
Surprise % | 9.50% | 28.60% | -50.00% | 0.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
7 Days Ago | -0.16 | -0.16 | -0.66 | -1.59 |
30 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
60 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
90 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | GALT | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 15.80% | -- | -- | 0.40% |
Next Qtr. | -6.70% | -- | -- | 9.90% |
Current Year | 10.80% | -- | -- | 4.30% |
Next Year | -140.90% | -- | -- | 13.40% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/9/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/1/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/15/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 5/17/2023 |
Reiterates | HC Wainwright & Co.: Buy | 3/3/2023 |
Maintains | HC Wainwright & Co.: Buy | 5/17/2022 |
Related Tickers
GLMD Galmed Pharmaceuticals Ltd.
0.3614
-0.63%
MDGL Madrigal Pharmaceuticals, Inc.
218.38
+2.29%
AUPH Aurinia Pharmaceuticals Inc.
5.09
+0.79%
SGMT Sagimet Biosciences Inc.
4.2800
+6.20%
HEPA Hepion Pharmaceuticals, Inc.
1.4900
+5.67%
GLYC GlycoMimetics, Inc.
1.8350
+1.94%
CRDF Cardiff Oncology, Inc.
4.1700
-4.36%
VSTM Verastem, Inc.
9.61
-1.33%
ADCT ADC Therapeutics SA
4.9700
+6.20%
ALT Altimmune, Inc.
7.57
+1.34%